Palatin Technologies, Inc. · AMEX:PTN
Palatin Technologies — Investor Presentation (September 2010)
30 slides from Palatin Technologies's investor presentation, Sep 14, 2010
Slide 1: Palatin Technologies Corporate Presentation
< > PALATIN TECHNOLOGIES Corporate Presentation September 2010
Slide 2: Forward-Looking Statement
” Y) Forward-Looking Statement The statements in this presentation that relate to future plans, events or performance are forward-looking statements, which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve s
Slide 3: Company Profile
Company Profile — Palatin is a biopharmaceutical company using proprietary approaches to develop peptide mimetic and small molecule agonists for the treatment of medical indications with significant unmet need and commercial potential Palatin’s has built compound libraries specific for the melanocor
Slide 4: Palatin Strategy
Palatin Strategy + Driving growth through developing our internal pipeline and collaborations — Acute or on-demand treatments with novel mechanisms for unmet needs — Establish safety and efficacy and extend development to chronic indications = Ondernand treatments: > sexual dysfunction FSD and ED =
Slide 5: Palatin Product Overview
. . <> alatin Product Overview aie e Bremelanotide (BMT), a melanocortin receptor (MCR) agonist, in clinical development as a treatment for female sexual dysfunction (FSD) and erectile dysfunction (ED) e PL-3994, a natriuretic peptide receptor A (NPR-A) agonist, for treatment of acute severe asthma,
Slide 6: Melanocortin and Natriuretic Receptor Programs Pipeline
Melanocortin Receptor (MCR) Programs Natriuretic Receptor Programs BMT MCR Compound (partnered with AstraZeneca) PL-6983 PL-3994 PL-3994 PL-3994 Pipeline Indication Obesity & Diabetes FSD & ED ‘Acute Severe Asthma Heart Failure Refractory Hypertension Preclinical Phase | Phase It Phase tll
Slide 7: Melanocortin Sexual Dysfunction Program
Melanocortin Sexual Dysfunction Program FSD and ED PDE-5 non-responders
Slide 8: Sexual Dysfunction Program Overview
e ; <> Sexual Dysfunction Program Overview mn * Extensive clinical experience with bremelanotide —- Evaluated in over 2000 patients - Demonstrated efficacy as a treatment for both FSD and ED * BMT subcutaneous (PRN) is in development for — Treatment of women with FSD - Treatment of ED as a monothera
Slide 9: Relative size of sexual dysfunction markets
% of market 10%, as ay ms ay ay as as ay 0% 0% Commercial Opportunity Presence Dent Make Value aFemde Seca! Dystincien Premature Gacuaton E ectle Dystntion Relative size of sexual dysfunction markets + FSDis a large untapped commercial opportunity — ~5im women in US have symptoms + ~10% - 20% of pat
Slide 10: Bremelanotide FSD Market Opportunity
Bremelanotide FSD Market Opportunity Female Sexual Dysfunction (FSD) encompasses a collection of sexual disorders that affect ~43% of adult women + No FDA approved treatments available * Significant unmet clinical need + FDA, patients and clinicians want effective treatment options 60-59 oar (2.7 mo
Slide 11: Bremelanotide ED Market Opportunity
Bremelanotide ED Market Opportunity 35% of patients are satisfied pe are cmerainal satisfied” but PDE-5 inhibitor users ave no alternative treatment options 35% discontinue PDE-5 inhibitor therapy following initial prescription jal Target Population BMT estimated global peak sales: $550 million 10%
Slide 12: Bremelanotide Clinical Experience
Bremelanotide Clinical Experience + Palatin has extensive clinical experience with BMT - Evaluated in 30 clinical studies intranasal (IN) or SC formulations — Demonstrated efficacy as a treatment for both FSD & ED * Commercializing SC formulation — Tight control of PK — Optimizes therapeutic opportu
Slide 13: Effects of Bremelanotide on SBP
Effects of Bremelanotide on SBP — BMT Phase 1 data in premenopausal women Subcutaneous administration —o+ BMT a Placebo “10 ‘Systolic Blood Pressure baseline (mmHg) ‘Change fram predose 15 19203 4 5 6 7 8 8 10 14 12 13 14 415 18
Slide 14: BMT in the Treatment of FSAD
BMT in the Treatment of FS = Multiple phase 2 studies have established proof-of-concept in women with FSAD Significant improvement in FDA accepted endpoints — Arousal, desire and satisfying sexual encounters — Decrease in distress caused by sexual dysfunction Women reported an improvement in the qua
Slide 15: Satisfying Sexual Events and Arousal Success Rate
Peloor P<0.008 #of SSE's oan wo awe BSL ‘mos. 2mos. Arousal Success Rate P<0.001 P<0.001 = i] 2 =] 20 OPlacebo BMT % Change from Baseline 10 1 mos. 2 mos. SSE: “Satisfying Sexual Events,” the FDA required registration endpoint and roughly equal to the number of orgasms experienced in a month Arousal
Slide 16: Bremelanotide FSAD Clinical Program
Bremelanotide FSAD Clinical Program <= : + Phase 2B in premenopausal women with FSAD — Dose ranging 12 week “at-home” placebo controlled study — FDA accepted endpoints * Improvement in arousal as measured by validated SEQ + Increase in SSE’s as measured by event log + Improvement in sexual distress
Slide 17: PDE-5 Inhibitor Responsive Patients
PDE-5 Inhibitor Responsive Patients <= = e Multiple BMT ED studies have demonstrated efficacy in a broad range of patients, including those non-responsive to PDE-S5 inhibitor treatment e Phase 2 clinical studies evaluating BMT co-administration with PDE-5 inhibitor demonstrate additive effect e Sign
Slide 18: Bremelanotide ED Clinical Program
Bremelanotide ED Clinical Program <= = + Bremelanotide phase 2A study PDE-5 inhibitor non-responsive ED patients — Dose optimization of bremelanotide as an adjunct to PDE-5 inhibitors — Treatment effect size in target non-responder population — Continued evaluation of effects on blood pressure — Tar
Slide 19: Natriuretic Peptide Receptor Programs
Natriuretic Peptide Receptor Programs
Slide 20: Acute Severe Asthma: current therapy
ute Severe Asthma: <> current therap raatin Drugs 2003, 68 (17): 2363-2391 asthma case fatalty rates (asthma deaths per 100 000 asthmatic petients in the S- to 34-year-old age group). Maal et a. 20
Slide 21: Pulmonary Commercial Opportunity
Pulmonary Commercial Opportunity ai ee] Market Potential >$500M [Nebulized | Market Potential >$1B Market Potential >$3B *Crossover use of asthma therapeutics in COPD approx. 30% of asthma market a
Slide 22: PL-3994 for Acute Severe Asthma
PL-3994 for Acute Severe Asthma — + Acute ED use Single or multiple subcutaneous or nebulized doses Patients are refractory to LABA bronchodilators Other bronchodilators ineffective PL-3994 dilates airway smooth muscle via a different mechanism (cGMP vs cAMP) Clinical precedent with short-acting end
Slide 23: Natriuretic Peptides and Asthma
Natriuretic Peptides and Asthma — « Published data demonstrate bronchodilator activity of IV and aerosol NPR-A agonists « NPR-A agonism relaxes smooth muscle in airways — effect is increased under conditions of 82 overload « NPR-A cGMP pathway is independent of 82-ADR/cAMP pathway ° Fe refractory, a
Slide 24: PL-3994 in Asthma Disease Models
PL-3994 in Asthma Disease Models semicon = zo ' & & & ' F Fa P1.3994 Dose 100 to * Iso © ISO + PL-agas 108 108 107 108 105 104 oso)m PL-2994 potentiated relaxation after soproterenal treatment 24
Slide 25: PL-3994 Clinical Results
PL-3994 Clinical Results — « Phase 1 & 2A placebo-controlled dose escalation studies — Well tolerated - no adverse or severe adverse events — Clear dose response for key pharmacological effects — Prolonged duration of effect — Met key pharmacology endpoints = SBP, tdiuresis, tnatriuresis, [cGMP plas
Slide 26: PL-3994 Asthma Development
PL-3994 Asthma Development — « Phase 2 proof-of-principle study in asthmatics — Inclinic SC dosing in stable asthmatics — Objective is to determine bronchodilator effect of PI-3994 — Target start 1Q11 « Nebulized formulation — Physical chemical studies — Animal toxicology program — Target phase 1 st
Slide 27: PL-3994 Additional Indication
PL-3994 Additional Indication iam * Sub-chronic HF Indication — Frequent hospitalization for worsening symptoms + Hospitalization leads to decreased survival + Identified by NIH Institute of Medicine as a high priority medical issue + Significant driver of hospital costs — PL-3994 treatment for 3-6
Slide 28: AstraZeneca Obesity Collaboration
AstraZeneca Obesity Collaboration — « AstraZeneca is a global pharmaceutical company with a strong emphasis in metabolic disease « Exclusive global licensing and research collaboration — $10M up front and $12M milestones received — Royalties on commercialization — $85M in development and $60M in sal
Slide 29: 2010-2011 Milestones
2010-2011 Milestones = « Bremelanotide phase 2B study in women with FSAD + Bremelanotide phase 2 study in ED patients non- responsive to PDE-5 inhibitor + PL-3994 phase 2 proof-of-principle study in asthmatic patients « AstraZeneca melanocortin obesity/diabetes program transition to clinical studies
Slide 30: Financial Snapshot
Financial Snapshot — Ticker Symbol NYSE AMEX: PTN 52-Week Price Range $0.15 - $0.48 Shares Outstanding — August 2010 » Common 117M » Fully Diluted 143M Market Capitalization — August 2010 $25M Cash and Investments Balance as of 3/31/10 $10.2M 30
Palatin Technologies — Investor Presentation (September 2010) on 6ix